Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

11.90
-0.0500-0.42%
Post-market: 11.980.0775+0.65%19:55 EDT
Volume:2.66M
Turnover:31.57M
Market Cap:1.64B
PE:-3.29
High:12.07
Open:12.00
Low:11.63
Close:11.95
52wk High:15.87
52wk Low:4.88
Shares:138.00M
Float Shares:107.00M
Volume Ratio:0.99
T/O Rate:2.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6118
EPS(LYR):-3.0800
ROE:-319.07%
ROA:-29.08%
PB:19.43
PE(LYR):-3.86

Loading ...

Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Oct 02

Compass Pathways Names Kelley Boucher Chief People Officer

Reuters
·
Sep 30

H.C. Wainwright Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

TIPRANKS
·
Sep 22

Compass Pathways Joins TD Cowen Novel Mechanisms in Neuropsychiatry Summit Fireside Chat

Reuters
·
Sep 16

As Trump Backs Psychedelics Research, FDA Weighs Safety and Access Standards

Reuters
·
Sep 15

Compass Pathways Launches ‘Change the Tune in Trd’ in the U.S. to Advance Hcp Understanding of Treatment-Resistant Depression at Psych Congress 2026

THOMSON REUTERS
·
Sep 15

Experts Urge FDA to Set Clear Safety and Access Standards for Psychedelic Drugs

Reuters
·
Sep 15

FDA to Hold Public Hearing on Psychedelic Drugs as Trump-Driven Push Gathers Pace

Reuters
·
Sep 15

Strata Mental Health Solutions awarded training grant by Compass Pathways

TIPRANKS
·
Sep 12

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval Comp360 Provider Training

THOMSON REUTERS
·
Sep 10

Compass Pathways Management Attends Investor Conference Fireside Chats in New York Week of Sept. 14

Reuters
·
Sep 10

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
Sep 10

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Sep 09

Compass Pathways Rises After One-Year Data for Psychedelic-Based Depression Drug

Reuters
·
Sep 09

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 Comp005 Trial Demonstrates Additional Benefit from Another Comp360 Dose in Part C Extending Durability Out to 1 Year

THOMSON REUTERS
·
Sep 09

Compass Pathways - Rolling Nda Submission Underway; Final Submission on Track for Q4

THOMSON REUTERS
·
Sep 09

Compass Pathways - Continue to Expect Commercial Launch in H1 2027

THOMSON REUTERS
·
Sep 09

Compass Pathways - Comp360 Safety Profile in Part C Consistent with Prior Parts; no New Safety Findings

THOMSON REUTERS
·
Sep 09

Compass Pathways - 25 Mg Arm Shows Average 13-Point Madrs Reduction at Week 52 with Durability to 1 Year

THOMSON REUTERS
·
Sep 09

Compass Pathways Grants Inducement Equity Awards Covering 414,100 Shares to New Hires

Reuters
·
Sep 04